Innovent Biopharmaceutical Transformation
R&D: Expanding Global Footprint of the R&D Organization
•
•
Innovent R&D
Led by Dr. Yongjun Liu
President, Innovent
1,500+ Global R&D Employees
Innovent Academy increased to ~300 talents based in China
and US. US wet lab put in operation in 2H 2021.
Organization: Immunology, Caner Biology, Protein Antibody
Engineering, Pharmacology & Toxicology
80 projects and 7 taskforce
6 molecules delivered to CMC
000
Chairman of the Department of Immunology; Founding
Director of the Center for Cancer Immunology Research
of MD Anderson Cancer Center
Global Head of Research of Sanofi
Established world-class Scientific Advisory Board, strong support
from global renowned scientists in SAB
Carlos Garcia-Echeverria,
Ph.D.
A
•
Suzhou R&D center, China
Maryland wet lab, US
Shanghai R&D center, China
Innover
Innovent
Lawrence Fong, M.D.
Lewis L. Lanier, Ph.D.
Chairman of the SAB
.
The Efim Guzik Distinguished
Professor in Cancer Biology in the
Helen Diller Family
•
The US National Academy of
Sciences
•
Comprehensive Cancer Center at
the University of California, San
Francisco, where he leads the
Cancer Immunotherapy Program
Co-director the Parker Institute of
Cancer Immunotherapy at UCSF
and co-leads the Cancer Immunity
and Immunotherapy Program in
the Cancer Center
•
The American Academy of Arts and
Sciences
American Cancer Society Professor
.
J. Michael Bishop MD Distinguished
Professor
Chairman of Microbiology and
Immunology at University of
California, San Francisco
Director of the Parker Institute for
Cancer Immunotherapy
An accomplished drug discovery
scientist and pharma executive,
focused on bringing new therapies
to patients in need
The Chief of Rx Creation at EQRX
Over past 25+ years' scientific
leadership to drug discovery and
early clinical development teams
across different modalities and
diseases at Sanofi as COO of
Research and at Novartis as
Oncology Drug Discovery Head
•
•
•
Confidential
Copyright©2022 Innovent
10View entire presentation